Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Integra Lifesciences Holdings (IART) Enterprise Value (2016 - 2025)

Integra Lifesciences Holdings' Enterprise Value history spans 17 years, with the latest figure at -$263.7 million for Q4 2025.

  • For Q4 2025, Enterprise Value rose 3.59% year-over-year to -$263.7 million; the TTM value through Dec 2025 reached -$263.7 million, up 3.59%, while the annual FY2025 figure was -$263.7 million, 3.59% up from the prior year.
  • Enterprise Value for Q4 2025 was -$263.7 million at Integra Lifesciences Holdings, down from -$232.2 million in the prior quarter.
  • Across five years, Enterprise Value topped out at -$232.2 million in Q3 2025 and bottomed at -$663.1 million in Q1 2024.
  • The 5-year median for Enterprise Value is -$308.3 million (2023), against an average of -$370.6 million.
  • The largest annual shift saw Enterprise Value plummeted 115.74% in 2024 before it surged 58.79% in 2025.
  • A 5-year view of Enterprise Value shows it stood at -$513.4 million in 2021, then fell by 7.83% to -$553.6 million in 2022, then soared by 49.86% to -$277.6 million in 2023, then rose by 1.45% to -$273.6 million in 2024, then grew by 3.59% to -$263.7 million in 2025.
  • Per Business Quant, the three most recent readings for IART's Enterprise Value are -$263.7 million (Q4 2025), -$232.2 million (Q3 2025), and -$253.6 million (Q2 2025).